{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:16:24Z","timestamp":1786990584643,"version":"build-2736575974"},"reference-count":141,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijgc.2025.102809","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:12:25Z","timestamp":1763701945000},"page":"102809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hormone replacement therapy in gynecologic cancer: oncologic safety and alternative therapies"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6007-0308","authenticated-orcid":false,"given":"Ana","family":"Luzarraga Aznar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8797-9538","authenticated-orcid":false,"given":"Osnat","family":"Elyashiv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7922-9486","authenticated-orcid":false,"given":"Susan","family":"Dababou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1054-3004","authenticated-orcid":false,"given":"Natalia Anna","family":"Palasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1114-4678","authenticated-orcid":false,"given":"Muhterem Melis","family":"Canturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-2903","authenticated-orcid":false,"given":"Rosa","family":"Montero-Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9791-9464","authenticated-orcid":false,"given":"Matteo","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-6876","authenticated-orcid":false,"given":"Aarthi S.","family":"Jayraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6817-0693","authenticated-orcid":false,"given":"Heng-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro T.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2025.102809_bib1","unstructured":"Ferlay J., Ervik M., Lam F., et al. Global cancer observatory: cancer today. version 1.1. Global Cancer Observatory. Lyon, France: International Agency for Research on Cancer; 2024. Accessed date: 14 April 2025. URL: https:\/\/gco.iarc.fr\/today\/en\/dataviz\/tables?mode=cancer&group_populations=1&multiple_populations=1&sexes=2"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102809_bib2","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3390\/jcm13051443","article-title":"Hormone replacement therapy in post-menopause hormone-dependent gynecological cancer patients: a narrative review","volume":"13","author":"Villa","year":"2024","journal-title":"J Clin Med"},{"issue":"10071","key":"10.1016\/j.ijgc.2025.102809_bib3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(16)31392-7","article-title":"The global burden of women\u2019s cancers: a grand challenge in global health","volume":"389","author":"Ginsburg","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/humupd\/dmac003","article-title":"Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis","volume":"28","author":"Khattak","year":"2022","journal-title":"Hum Reprod Update"},{"issue":"10430","key":"10.1016\/j.ijgc.2025.102809_bib5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0140-6736(23)02802-7","article-title":"Managing menopause after cancer","volume":"403","author":"Hickey","year":"2024","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/20533691241286666","article-title":"British Gynaecological Cancer Society and British Menopause Society guidelines: management of menopausal symptoms following treatment of gynaecological cancer","volume":"30","author":"Taylor","year":"2024","journal-title":"Post Reprod Health"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgaa764","article-title":"The menopause transition: signs, symptoms, and management options","volume":"106","author":"Santoro","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"30","key":"10.1016\/j.ijgc.2025.102809_bib8","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.23.01918","article-title":"Menopausal hormone therapy and ovarian and endometrial cancers: long-term follow-up of the Women\u2019s Health Initiative randomized trials","volume":"42","author":"Chlebowski","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102809_bib9","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/jog.15653","article-title":"Hormone replacement therapy and cancer risks in perimenopausal women: a retrospective cohort study using a Japanese claims database","volume":"49","author":"Inayama","year":"2023","journal-title":"J Obstet Gynaecol Res"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102809_bib10","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1016\/S1470-2045(24)00262-6","article-title":"Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE","volume":"25","author":"Morice","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib11","first-page":"393","article-title":"Ovarian tissue cryopreservation versus other fertility techniques for chemoradiation-induced premature ovarian insufficiency in women: a systematic review and future directions","volume":"14","author":"Chaudhri","year":"2024","journal-title":"Life (Basel)"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12253-018-00569-x","article-title":"Hormone replacement therapy in cancer survivors - review of the literature","volume":"26","author":"Deli","year":"2020","journal-title":"Pathol Oncol Res"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102809_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.6004\/jnccn.2015.0106","article-title":"Menopausal hormone therapy influence on breast cancer outcomes in the Women\u2019s Health Initiative","volume":"13","author":"Chlebowski","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11864-025-01298-5","article-title":"Updates in hormone replacement therapy for survivors of gynecologic cancers","volume":"26","author":"Gorman","year":"2025","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ijgc-2019-001034","article-title":"Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma","volume":"30","author":"Chambers","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102809_bib17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/AOG.0000000000000526","article-title":"Vaginal estrogen for genitourinary syndrome of menopause: a systematic review","volume":"124","author":"Rahn","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102809_bib18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/GME.0000000000000790","article-title":"TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol","volume":"24","author":"Archer","year":"2017","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/GME.0000000000001463","article-title":"Systemic estradiol levels with low-dose vaginal estrogens","volume":"27","author":"Santen","year":"2020","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102809_bib20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study","volume":"135","author":"Le Ray","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102809_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ajog.2019.08.043","article-title":"Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy","volume":"222","author":"Crean-Tate","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.6118\/jmm.24011","article-title":"Treatment of genitourinary syndrome of menopause in breast cancer and gynecologic cancer survivors: retrospective analysis of efficacy and safety of vaginal estriol, vaginal dehydroepiandrosterone and ospemifene","volume":"30","author":"Pennacchini","year":"2024","journal-title":"J Menopausal Med"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib23","first-page":"1335","article-title":"Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102809_bib24","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/AOG.0000000000004601","article-title":"Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus","volume":"138","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102809_bib25","first-page":"767","article-title":"\u201cThe 2022 Hormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","year":"2022","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jcem.87.1.8141","article-title":"Tibolone for postmenopausal women: systematic review of randomized trials","volume":"87","author":"Modelska","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.maturitas.2005.02.011","article-title":"Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group","volume":"51","author":"Kenemans","year":"2005","journal-title":"Maturitas"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102809_bib28","article-title":"Short-term and long-term effects of tibolone in postmenopausal women","volume":"10","author":"Formoso","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102809_bib29","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/ijc.31267","article-title":"Tibolone and risk of gynecological hormone sensitive cancer","volume":"142","author":"L\u00f8kkegaard","year":"2018","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.6118\/jmm.23032","article-title":"Tibolone and breast cancer","volume":"29","author":"Lee","year":"2023","journal-title":"J Menopausal Med"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102809_bib31","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1210\/jc.2004-1747","article-title":"Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder","volume":"90","author":"Simon","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102809_bib32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2213-8587(19)30189-5","article-title":"Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data","volume":"7","author":"Islam","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102809_bib33","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/13697137.2019.1637079","article-title":"Global consensus position statement on the use of testosterone therapy for women","volume":"22","author":"Davis","year":"2019","journal-title":"Climacteric"},{"key":"10.1016\/j.ijgc.2025.102809_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.maturitas.2020.06.021","article-title":"No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA)","volume":"142","author":"Cai","year":"2020","journal-title":"Maturitas"},{"key":"10.1016\/j.ijgc.2025.102809_bib35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.maturitas.2018.11.017","article-title":"Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation of tolerability and safety","volume":"121","author":"Di Donato","year":"2019","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib37","first-page":"417","article-title":"Adenocarcinoma of the endometrium in women 40 years of age or younger","volume":"64","author":"Gallup","year":"1984","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","article-title":"Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study","volume":"24","author":"Barakat","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib40","first-page":"326","article-title":"Estrogen replacement therapy in the patient treated for endometrial cancer","volume":"67","author":"Creasman","year":"1986","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102809_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0090-8258(90)90171-G","article-title":"Estrogen replacement therapy following treatment for stage I endometrial carcinoma","volume":"36","author":"Lee","year":"1990","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102809_bib42","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0002-9378(96)70027-3","article-title":"Estrogen replacement in surgical stage I and II endometrial cancer survivors","volume":"175","author":"Chapman","year":"1996","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib43","first-page":"555","article-title":"Estrogen replacement therapy in endometrial cancer patients: a matched control study","volume":"97","author":"Suriano","year":"2001","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102809_bib44","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ijgc-00009577-200603000-00054","article-title":"Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?","volume":"16","author":"Ayhan","year":"2006","journal-title":"Int J Gynecol Cancer"},{"issue":"14","key":"10.1016\/j.ijgc.2025.102809_bib45","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.ijgc.2025.102809_bib46","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102809_bib47","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejca.2014.03.006","article-title":"Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis","volume":"50","author":"Shim","year":"2014","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102809_bib48","article-title":"Hormone replacement therapy for women previously treated for endometrial cancer","volume":"5","author":"Edey","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"issue":"14","key":"10.1016\/j.ijgc.2025.102809_bib49","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.3390\/jcm10143165","article-title":"Hormone replacement therapy in endometrial cancer survivors: a meta-analysis","volume":"10","author":"Londero","year":"2021","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102809_bib50","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.23717","article-title":"Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy?","volume":"113","author":"Maxwell","year":"2008","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.ijgc.2025.102809_bib51","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.3390\/cancers14133090","article-title":"Postoperative hormone replacement therapy and survival in women with ovarian cancer","volume":"14","author":"Ji","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102809_bib52","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1002\/ijc.22218","article-title":"Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival","volume":"119","author":"Mascarenhas","year":"2006","journal-title":"Int J Cancer"},{"issue":"35","key":"10.1016\/j.ijgc.2025.102809_bib53","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial","volume":"33","author":"Eeles","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102809_bib54","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/bjc.2015.377","article-title":"Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study","volume":"113","author":"Be\u0161evi\u0107","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib55","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3892\/ol.2011.461","article-title":"Impact of post-operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy","volume":"3","author":"Li","year":"2012","journal-title":"Oncol Lett"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102809_bib56","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1","article-title":"Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial","volume":"86","author":"Guidozzi","year":"1999","journal-title":"Cancer"},{"issue":"7528","key":"10.1016\/j.ijgc.2025.102809_bib57","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib58","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e70","article-title":"Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey","volume":"35","author":"Palaia","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102809_bib59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.maturitas.2020.01.005","article-title":"European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis","volume":"134","author":"Rees","year":"2020","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib60","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2005.05.019","article-title":"The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study","volume":"99","author":"Akhan","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib61","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2011.11.009","article-title":"Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma","volume":"124","author":"Leitao","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib62","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.23245","article-title":"Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy","volume":"112","author":"Kapp","year":"2008","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102809_bib63","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3390\/medicina58091140","article-title":"Is adnexectomy mandatory at the time of hysterectomy for uterine sarcomas? A systematic review and meta-analysis","volume":"58","author":"Ronsini","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.ijgc.2025.102809_bib64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13569-015-0024-0","article-title":"Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital","volume":"5","author":"Thanopoulou","year":"2015","journal-title":"Clin Sarcoma Res."},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib65","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ygyno.2005.11.010","article-title":"Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature","volume":"101","author":"Pink","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102809_bib66","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/cancers15020356","article-title":"Impact of hormone replacement therapy on the overall survival and progression free survival of ovarian cancer patients: a systematic review and meta-analysis","volume":"15","author":"Achima\u015f-Cadariu","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib67","article-title":"Hormone replacement therapy after surgery for epithelial ovarian cancer","volume":"1","author":"Saeaib","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"10.1016\/j.ijgc.2025.102809_bib68","first-page":"192","article-title":"Hormone replacement therapy after epithelial ovarian cancer treatment","volume":"21","author":"Bebar","year":"2000","journal-title":"Eur J Gynaecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib69","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.maturitas.2009.11.017","article-title":"Hormone replacement after gynaecological cancer","volume":"65","author":"Singh","year":"2010","journal-title":"Maturitas"},{"issue":"6771","key":"10.1016\/j.ijgc.2025.102809_bib70","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/bmj.302.6771.259","article-title":"Hormone replacement therapy and survival after surgery for ovarian cancer","volume":"302","author":"Eeles","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.ijgc.2025.102809_bib71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2018.02.005","article-title":"Hormone replacement therapy in cancer survivors: utopia?","volume":"124","author":"Angioli","year":"2018","journal-title":"Crit Rev Oncol Hematol."},{"issue":"2","key":"10.1016\/j.ijgc.2025.102809_bib72","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ygyno.2011.03.012","article-title":"Hormone replacement therapy in gynecologic cancer survivors: why not?","volume":"122","author":"Ibeanu","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"16","key":"10.1016\/j.ijgc.2025.102809_bib73","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1002\/cncr.25929","article-title":"Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma","volume":"117","author":"Schlumbrecht","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102809_bib74","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib75","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/jcp.2006.040030","article-title":"Ovarian clear cell adenocarcinoma: a continuing enigma","volume":"60","author":"Tan","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ijgc.2025.102809_bib76","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bpobgyn.2021.11.005","article-title":"The use of menopausal hormone therapy after cancer","volume":"81","author":"Brennan","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib77","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/ijgc-2020-002032","article-title":"Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer","volume":"31","author":"Brennan","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib78","first-page":"337","article-title":"[Borderline ovarian tumours: CNGOFS guidelines for clinical practice - hormonal contraception and MHT\/HRT after borderline ovarian tumour]","volume":"48","author":"Rousset-Jablonski","year":"2020","journal-title":"Gynecol Obstet Fertil Senol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102809_bib79","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.clon.2016.08.016","article-title":"Iatrogenic menopause after treatment for cervical cancer","volume":"28","author":"Moss","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib80","first-page":"322","article-title":"Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022","volume":"5","author":"Wu","year":"2025","journal-title":"J Natl Cancer Cent"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102809_bib81","doi-asserted-by":"crossref","first-page":"584","DOI":"10.5468\/ogs.2018.61.5.584","article-title":"Effect of tibolone on the survival of early stage cervical adenocarcinoma patients","volume":"61","author":"Lee","year":"2018","journal-title":"Obstet Gynecol Sci"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib82","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/20533691211028518","article-title":"Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma","volume":"27","author":"Richardson","year":"2021","journal-title":"Post Reprod Health"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102809_bib83","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0090-8258(87)90270-8","article-title":"Hormonal replacement therapy in patients after cervical cancer treatment","volume":"26","author":"Ploch","year":"1987","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102809_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2024.108004","article-title":"Hormone replacement therapy in women with iatrogenic premature ovarian insufficiency after radiotherapy for cervical cancer: a retrospective cohort and survey study","volume":"185","author":"van der Hoef","year":"2024","journal-title":"Maturitas"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102809_bib85","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/GME.0000000000000357","article-title":"Hormone therapy after uterine cervical cancer treatment: a Swedish population-based study","volume":"22","author":"Everhov","year":"2015","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib86","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ygyno.2017.09.009","article-title":"Hormone replacement therapy after treatment for cervical cancer: are we adhering to standard of care?","volume":"147","author":"Rauh","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib87","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/ijgc-2022-003861","article-title":"Prescription of hormone replacement therapy among cervical cancer patients with treatment-induced premature menopause","volume":"33","author":"Suzuki","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.102809_bib88","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7513610","article-title":"Impact of ospemifene on quality of life and sexual function in young survivors of cervical cancer: a prospective study","volume":"2017","author":"De Rosa","year":"2017","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ijgc.2025.102809_bib89","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102809_bib90","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/M19-0274","article-title":"Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: a randomized trial","volume":"171","author":"Manson","year":"2019","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102809_bib91","first-page":"e281","article-title":"Hormone replacement therapy and colorectal cancer incidence and mortality in the prostate, Lung, colorectal, and ovarian cancer screening trial","volume":"17","author":"Symer","year":"2018","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib92","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","volume":"22","author":"P\u00f6tter","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102809_bib93","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/ijgc-2023-004429","article-title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with cervical cancer - update 2023","volume":"33","author":"Cibula","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102809_bib94","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/jog.15406","article-title":"Assessment of long-term sexual function of cervical cancer survivors after treatment: a cross-sectional study","volume":"48","author":"Wang","year":"2022","journal-title":"J Obstet Gynaecol Res"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102809_bib95","first-page":"1005","article-title":"Immunohistochemical investigations of estrogen receptors in normal and neoplastic squamous epithelium of the vulva","volume":"35","author":"Mosny","year":"1990","journal-title":"J Reprod Med"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102809_bib96","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1365-2559.2011.04029.x","article-title":"Cytoplasmic expression of oestrogen receptor beta (ER\u03b2) as a prognostic factor in vulvar squamous cell carcinoma in elderly women","volume":"59","author":"Zannoni","year":"2011","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102809_bib97","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/PAS.0b013e3181590ba4","article-title":"Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases","volume":"32","author":"Robson","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102809_bib98","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1447-0756.2011.01554.x","article-title":"Primary adenoid cystic carcinoma of sweat glands in vulva: report of an unusual case and review of the literature","volume":"37","author":"Tang","year":"2011","journal-title":"J Obstet Gynaecol Res"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib99","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.4081\/rt.2013.e40","article-title":"Apocrine adenocarcinoma of the vulva","volume":"5","author":"Kajal","year":"2013","journal-title":"Rare Tumors"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib100","first-page":"213","article-title":"Adenoid cystic carcinoma of Bartholin\u2019s gland: a case report","volume":"22","author":"Krasevi\u0107","year":"2001","journal-title":"Eur J Gynaecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102809_bib101","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/03008916231208308","article-title":"Management of primary and recurrent Bartholin\u2019s gland carcinoma: a systematic review on behalf of MITO Rare Cancer Group","volume":"110","author":"Turetta","year":"2024","journal-title":"Tumori"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib102","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00403-024-03791-7","article-title":"Unraveling the controversy: exploring the link between sex hormones and skin cancers through a meta-analysis and systematic review","volume":"317","author":"Zhao","year":"2025","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib103","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41416-024-02767-8","article-title":"Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records","volume":"131","author":"Cardwell","year":"2024","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib104","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/sj.bjc.6601595","article-title":"Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma","volume":"90","author":"MacKie","year":"2004","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102809_bib105","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/modpathol.3800437","article-title":"Androgen receptors are frequently expressed in mammary and extramammary Paget\u2019s disease","volume":"18","author":"Liegl","year":"2005","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102809_bib106","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ygyno.2020.01.035","volume":"157","author":"Sinno","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib107","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/cancers15030711","article-title":"Long-Term non-cancer Risks in People with BRCA Mutations following Risk-Reducing bilateral salpingo-oophorectomy and the Role of hormone replacement therapy: a review","volume":"15","author":"Nitschke","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib108","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits","volume":"153","author":"Gordhandas","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102809_bib109","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10549-021-06436-9","article-title":"Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis","volume":"191","author":"Poggio","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10689-015-9798-8","article-title":"Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study","volume":"14","author":"Segev","year":"2015","journal-title":"Fam Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102809_bib111","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jnci\/djab036","article-title":"Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations: multicenter cohort study","volume":"113","author":"de Jonge","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.ijgc.2025.102809_bib112","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1002\/cncr.29464","article-title":"Estrogen and colorectal cancer incidence and mortality","volume":"121","author":"Lavasani","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib113","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"issue":"30","key":"10.1016\/j.ijgc.2025.102809_bib114","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2014.60.7366","article-title":"A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial","volume":"33","author":"Goetsch","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102809_bib115","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 nonhormone therapy position statement of the North American Menopause Society","volume":"30","year":"2023","journal-title":"Menopause"},{"key":"10.1016\/j.ijgc.2025.102809_bib116","first-page":"105","article-title":"Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy","volume":"1","author":"Kingsberg","year":"2010","journal-title":"Int J Womens Health"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102809_bib117","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamainternmed.2018.0116","article-title":"Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial","volume":"178","author":"Mitchell","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib118","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1186\/s12885-023-11656-x","article-title":"Vaginal CO2 laser therapy for genitourinary syndrome in breast cancer survivors-VagLaser study protocol: a randomized blinded, placebo-controlled trial","volume":"23","author":"Jacobsen","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijgc.2025.102809_bib119","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejogrb.2022.08.012","article-title":"Fractional Co2 laser for vulvo-vaginal atrophy in gynecologic cancer patients: a valid therapeutic choice? A systematic review","volume":"277","author":"D\u2019Oria","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102809_bib120","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3390\/cancers12061639","article-title":"Results of a phase I-II study on laser therapy for vaginal side effects after radiotherapy for cancer of uterine cervix or endometrium","volume":"12","author":"Perrone","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijgc.2025.102809_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2022.08.013","article-title":"Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: a randomized controlled trial","volume":"167","author":"Gold","year":"2023","journal-title":"Maturitas"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102809_bib122","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/gme.0b013e31823fe835","article-title":"Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial","volume":"19","author":"Ayers","year":"2012","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib123","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(11)70364-3","article-title":"Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial","volume":"13","author":"Mann","year":"2012","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102809_bib124","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/pon.5432","article-title":"Effectiveness of nurse-led group CBT for hot flushes and night sweats in women with breast cancer: results of the MENOS4 randomised controlled trial","volume":"29","author":"Fenlon","year":"2020","journal-title":"Psycho-oncology"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102809_bib125","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1200\/JCO.18.00655","article-title":"Efficacy of Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors: results of a randomized controlled trial","volume":"37","author":"Atema","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102809_bib126","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GME.0000000000001048","article-title":"Self-help cognitive behavior therapy for working women with problematic hot flushes and night sweats (MENOS@Work): a multicenter randomized controlled trial","volume":"25","author":"Hardy","year":"2018","journal-title":"Menopause"},{"issue":"31","key":"10.1016\/j.ijgc.2025.102809_bib127","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1200\/JCO.2008.16.6389","article-title":"Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors","volume":"26","author":"Elkins","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib128","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/gme.0b013e31826ce3ed","article-title":"Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial","volume":"20","author":"Elkins","year":"2013","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102809_bib129","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00404-015-3900-1","article-title":"Comparison of citalopram and venlafaxine\u2019s role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial","volume":"293","author":"Davari-Tanha","year":"2016","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.2010.2016","article-title":"Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial","volume":"305","author":"Freeman","year":"2011","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102809_bib131","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1001\/jamainternmed.2014.1891","article-title":"Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial","volume":"174","author":"Joffe","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib132","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000348564","article-title":"Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials","volume":"75","author":"Sun","year":"2013","journal-title":"Gynecol Obstet Investig"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102809_bib133","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/1471-0528.13951","article-title":"Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis","volume":"123","author":"Wei","year":"2016","journal-title":"BJOG"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib134","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bone.2009.07.083","article-title":"Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management?","volume":"46","author":"Haney","year":"2010","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102809_bib135","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/injuryprev-2014-041483","article-title":"SSRI use and risk of fractures among perimenopausal women without mental disorders","volume":"21","author":"Sheu","year":"2015","journal-title":"Inj Prev"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102809_bib136","doi-asserted-by":"crossref","first-page":"E1732","DOI":"10.1210\/jc.2014-2288","article-title":"Effects of escitalopram on markers of bone turnover: a randomized clinical trial","volume":"99","author":"Diem","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib137","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/GME.0000000000001491","article-title":"Gabapentin for the treatment of hot flushes in menopause: a meta-analysis","volume":"27","author":"Yoon","year":"2020","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102809_bib138","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.AOG.0000222383.43913.ed","article-title":"Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial","volume":"108","author":"Reddy","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"10382","key":"10.1016\/j.ijgc.2025.102809_bib139","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102809_bib140","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/AOG.0000000000005508","article-title":"Efficacy and safety of fezolinetant for the treatment of menopause-associated vasomotor symptoms: a meta-analysis","volume":"143","author":"Bonga","year":"2024","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102809_bib141","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/AOG.0000000000005114","article-title":"Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial","volume":"141","author":"Neal-Perry","year":"2023","journal-title":"Obstet Gynecol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:21:10Z","timestamp":1780003270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25019310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":141,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1048891X25019310"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102809","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormone replacement therapy in gynecologic cancer: oncologic safety and alternative therapies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102809"}}